Jun 10 |
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
|
May 16 |
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
|
May 12 |
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
|
May 8 |
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
|
May 7 |
MoonLake Immunotherapeutics EPS of -$0.22 misses by $0.01
|
May 7 |
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
|
Apr 10 |
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
|
Apr 2 |
Goldman starts MoonLake at neutral, cites lead drug potential
|
Mar 11 |
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
|
Mar 10 |
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
|